retatrutide nonalcoholic fatty liver disease trial nash Researchers report promising results with retatrutide, which significantly reduced fat in some patients over several months. Excess liver fat causes metabolic dysfunction–associated steatotic Researchers are reporting promising results

"With the introduction of branded products such as the Wegovy pill and Wegovy pen, we are already seeing our addressable market expand significantly

Thus, patients treated with liraglutide reported reduced alcohol intake compared to patients who received other diabetic treatments ( GLP-1R gene ( GLP-1R polymorphisms are associated with higher breath concentrations of alcohol and increased intravenous infusion of alcohol in social drinkers (Tsermpini et al., 2022)

They are not licensed medicines, do not go through the same testing, and are not prescribed by healthcare professionals

But are they really necessary and, more importantly, do they work as advertised